alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
## Detailed Single Year Tables

- Individual Provisions
- Level of Monthly Benefits

### **Description of Proposed Provision:						B5.9: Beginning for those newly eligible in 2025, reconfigure the special minimum benefit: (a) A year of coverage is defined as a year in which 4 quarters of coverage are earned. (b) At implementation, set the PIA for 40 years of coverage equal to 125 percent of the monthly Aged Federal poverty level (about $1,462 in 2022). For those with 20 or fewer years of coverage, phase up linearly from 0 percent of the poverty level for 10 years of coverage to 100 percent of the poverty level. For those having between 20 and 40 years of coverage, phase up linearly from 100 percent of the poverty level at 20 years of coverage to 125% of the poverty level for 40 or more years of coverage. (c) For newly eligible workers in 2025 and 2026, index the applicable poverty level using the CPI index, to the year prior to eligibility. Then, for newly eligible workers in 2027 and later, index the PIA per year of coverage by wage growth for successive cohorts. (d) Disabled workers have a somewhat similar minimum benefit, with work requirements scaled based on the number of years of non-disabled potential work.**

### Financial Estimates for the OASDI Trust Fund Program

### Summarized Estimates
Exhibit 32.2

SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Gary S. Titus, Senior Vice President
and Chief Financial Officer of SciClone Pharmaceuticals, Inc. (the Registrant), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:



|(1) | the Annual Report on Form 10-K/A of the Registrant, to which this certification is attached as an exhibit (the Report), fully complies with the requirements
of section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------



|                       |  |  |  |                                                                                
|---------------------- |  |  |  | -------------------------------------------------------------------------------
|Date: December 6, 2010 |  |  |  | /S/    GARY S. TITUS                                                           
|                       |  |  |  | Gary S. Titus                                                                  
|                       |  |  |  | Senior Vice President and Chief Financial Officer
(Principal Financial Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the
electronic version of this written statement required by Section 906, has been provided to SciClone Pharmaceuticals, Inc. and will be retained by SciClone Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its
staff upon request.
| Skip to contentSocial Security Online | Actuarial Publications |
|---------------------------------------|------------------------|

| www.socialsecurity.gov | Home  FAQs  Contact Us  Search | **Search**  |
|------------------------|-----------------------------------------------------------------|------------------|

| Actuarial Publications | Summary of Provisions That Would Change the Social Security Program |
|------------------------|---------------------------------------------------------------------|

| Solvency Provisions | Description of Proposed Provisions:              Provisions Affecting Taxation of Benefits |
|---------------------|---------------------------------------------------------------------------------------------|
|                     |

*Estimates based on the intermediate assumptions of         the 2008 Trustees Report*

|        |
|--------|
|   | Privacy Policy      | Website Policies        & Other Important Information      | Site Map     Last reviewed or modified November 13, 2008 |
**Exhibit 13.2**

**CERTIFICATION**

**PURSUANTTO 18 U.S.C. SECTION 1350, AS ENACTED PURSUANT**

**TO SECTION 906 OF THE U.S. SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report of Intertape Polymer Group Inc. (the “Company”) on Form 20-F for the fiscal year endedDecember 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey Crystal, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adoptedpursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: 

1. The Report fully complies with the requirements ofSection 13(a) or 15(d) of the Securities Exchange Act of 1934; and 

2. The information contained in the Report fairly presents, inall material respects, the financial condition and results of operations of the Company. 

Date: March 31, 2016
#### STATE v. EUNICE MARTIN.

(Filed 18 December, 1946.)

Appeal by defendant from *Pless, J.,*at May Term, 1946, of Forsyth.

Criminal prosecution tried upon indictment charging defendant with the murder of one Bernice Martin.

Verdict: Guilty of murder in the first degree. Judgment: Death by asphyxiation.

Defendant appeals to the Supreme Court and assigns error.

*Attorney-General McMullan and Assistant Attorneys-General Bruton, Rhodes, and Moody for the State.*

*W. Reade Johnson and James M. Hayes for defendant.*

Denny, J.

We have carefully considered all the defendant’s exceptions and they are without merit. Moreover, a careful examination of the entire record leads us to the conclusion that the defendant has been given a fair and impartial trial, free from error. Every contention of the defendant was given in his Honor’s charge to the jury. A charge in which the defendant admits there is no error and to which he entered no exception.

No error.
<PAGE>   1
                                                                Exhibit 23.2

                         INDEPENDENT AUDITORS' CONSENT

We consent to the incorporation by reference in Registration Statement No.
33-87314, 33-53298, 33-48766, 33-71964 and 333-12139 of Cayenne Software, Inc.
on Form S-8 and Registration Statement No. 33-99956 and 33-89940 of Cayenne
Software, Inc. on Form S-3 of our report dated February 2, 1996 (relating to
the consolidated financial statements of Cadre Technologies Inc. and
subsidiaries) appearing in this Annual Report on Form 10-K of Cayenne Software,
Inc. for the transition period ended December 31, 1996.


Deloitte & Touche LLP
Boston, MA

March 28, 1997
Long-range 

actuarial 

balance

Annual 

balance in 

75th year

Long-range 

actuarial 

balance

Annual 

balance in 

75th year

Long-range 

actuarial 

balance

Annual 

balance in 

75th year

-3.61 -4.35 0.01 0.01 0% 0%

Estimates based on the intermediate assumptions of the 2023 Trustees Report Office of the Chief Actuary

Social Security Administration

August 1, 2023

Summary Measures and Graphs

Category of Change: Taxation of Benefits

Current law

[percent of payroll]

Change from current law

[percent of payroll] Shortfall eliminated

Proposed Provision: H5. Beginning in 2030, for single/head-of-household/married-filing-separate taxpayers 

with MAGI of $250,000 or more and joint filers with MAGI of $500,000 or more, include up to the remaining 

15 percent of Social Security benefits in taxable income (increased from up to 85 percent of benefits 

taxable under current law). In subsequent years, update these thresholds for growth in wages (AWI). 

Revenue from this provision would be credited to the Social Security trust funds. Current law taxation of up 

to 85 percent of Social Security benefits would remain unchanged.

6.0

8.0

10.0

12.0

14.0

16.0

18.0

20.0

2023 2030 2040 2050 2060 2070 2080 2090

Percent

Year

OASDI Cost Rates and Income Rates

(as a percentage of taxable payroll)

Income rates under current law

Income rates with this provision

Cost rates under current law

Cost rates with this provision

0

100

200

300

400

500

600

2023 2030 2040 2050 2060 2070 2080 2090

Percent

Year

OASDI Trust Fund Ratio

(assets as a percentage of annual expenditures)

Current law With this provision
#### STATE v. DUNCAN THOMAS.

(Filed 22 May, 1946.)

Criminal Law § 78e—

An exception to the charge for failure to “charge the law and facts relative to this case” is an unpointed broadside exception.

Appeal by defendant from *Burney, J.,*at November Term, 1945, of Hoee. Motion to affirm the judgment allowed.

The defendant was charged in two bills of indictment with receiving stolen goods knowing them to have been stolen. From judgment upon verdict of guilty in both cases, the defendant appealed.

*Attorney-General McMullan and Assistant Attorney-General Rhodes for the State.*

*Franklin S. Clark and H. S. Kirkpatrick for defendant, appellant.*

Per Curiam.

The defendant’s only exception was to the charge of the court for failure to “charge the law and facts relative to this case.” As frankly admitted in defendant’s brief this is unpointed broadside. *Rawls v. Lupton,*193 N. C., 428, 137 S. E., 175. The record shows the trial free from error. The Attorney-General moves in this Court that the judgment below be affirmed. The defendant does not resist the motion.

The motion is allowed, and the judgment

Affirmed.
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                    8,356
<ALLOWANCES>                                       656
<INVENTORY>                                      5,903
<CURRENT-ASSETS>                                15,626
<PP&E>                                          53,146
<DEPRECIATION>                                  18,309
<TOTAL-ASSETS>                                  61,072
<CURRENT-LIABILITIES>                           11,413
<BONDS>                                         13,335
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           640
<OTHER-SE>                                      31,924
<TOTAL-LIABILITY-AND-EQUITY>                    61,072
<SALES>                                         46,666
<TOTAL-REVENUES>                                63,524
<CGS>                                           29,348
<TOTAL-COSTS>                                   42,318
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               1,960
<INCOME-PRETAX>                                 13,615
<INCOME-TAX>                                     6,201
<INCOME-CONTINUING>                              7,383
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     7,383
<EPS-BASIC>                                       1.22
<EPS-DILUTED>                                     1.19


</TABLE>
<PAGE>
                                  EXHIBIT 32.1

                            Certification Pursuant to
                             18 U.S.C. Section 1350,
                             As Adopted Pursuant to
                  Section 906 of the Sarbanes-Oxley Act of 2002


In connection with the Annual Report of CSB Bancorp, Inc. (the "Company") on
Form 10-K for the fiscal year ended December 31, 2003, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, John J.
Limbert, Chairman of the Board, President and Chief Executive Officer of the
Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

      (1) The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934, and

      (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

                                               /s/ John J. Limbert
                                               --------------------------------
                                               John J. Limbert
                                               Chairman of the Board, President
                                               and Chief Executive Officer

March 30, 2004
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL   INFORMATION  EXTRACTED  FROM  THE
CONSOLIDATED  FINANCIAL STATEMENTS AS OF DECEMBER 31, 1999 AND FOR THE YEAR THEN
ENDED.  THIS  INFORMATION  IS  QUALIFIED  IN ITS  ENTIRETY BY  REFERENCE TO SUCH
CONSOLIDATED FINANCIAL STATEMENTS
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                             DEC-31-1999
<PERIOD-END>                                  DEC-31-1999
<CASH>                                          2,879,300
<SECURITIES>                                            0
<RECEIVABLES>                                   3,748,700
<ALLOWANCES>                                     (35,000)
<INVENTORY>                                             0
<CURRENT-ASSETS>                                6,857,500
<PP&E>                                          1,383,700
<DEPRECIATION>                                  (609,200)
<TOTAL-ASSETS>                                 16,144,400
<CURRENT-LIABILITIES>                           4,645,066
<BONDS>                                                 0
<PREFERRED-MANDATORY>                                   0
<PREFERRED>                                             0
<COMMON>                                           56,200
<OTHER-SE>                                     10,599,200
<TOTAL-LIABILITY-AND-EQUITY>                   16,144,400
<SALES>                                                 0
<TOTAL-REVENUES>                               16,524,600
<CGS>                                                   0
<TOTAL-COSTS>                                  13,647,400
<OTHER-EXPENSES>                                        0
<LOSS-PROVISION>                                        0
<INTEREST-EXPENSE>                                      0
<INCOME-PRETAX>                                 4,146,900
<INCOME-TAX>                                    1,615,700
<INCOME-CONTINUING>                                     0
<DISCONTINUED>                                          0
<EXTRAORDINARY>                                         0
<CHANGES>                                               0
<NET-INCOME>                                    2,531,200
<EPS-BASIC>                                          0.46
<EPS-DILUTED>                                        0.43



</TABLE>
|EXHIBIT 23.1


CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM







We
consent to the incorporation by reference in the Registration Statements (Form S-8
Nos.33-87908, 333-18347,  333-55821, 333-57580 and 333-115719) and related Prospectuses
of Palomar Medical Technologies, Inc. of our reports dated March 7, 2005, with respect to
the consolidated financial statements of Palomar Medical Technologies, Inc., Palomar
Medical Technologies, Inc. managements assessment of the effectiveness of internal
control over financial reporting, and the effectiveness of internal control over
financial reporting of Palomar Medical Technologies, Inc. included in the Annual Report
(Form 10-K) for the year ended December 31, 2005.
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|                      |                      
|--------------------- | ---------------------
|                      | /s/ Ernst & Young LLP
|                      |                      
|                      |                      
|Boston, Massachusetts |                      
|March 2, 2006         |                      

|
|
#### DR. FRANK H. ROBINSON v. BILTMORE DAIRY FARMS, INC., and CHARLES LANE.

(Filed 24 November, 1937.)

Apreal by plaintiff from *Ervin, Special Judge,*and a jury, at 22 February, 1937, Extra Civil Term, of MeckleNburg. No error.

This is an action for actionable negligence, brought by plaintiff against defendants. The issues submitted to the jury and their answers thereto were as follows:

“1. Was the plaintiff Dr. Frank H. Robinson injured in his person and property by the negligence of the defendants Biltmore Dairy Farms, Inc., and Charles Lane, as alleged in the complaint? Ans.: Ño.’

“2. If so, did the plaintiff Dr. Frank H. Robinson, by his own negligence, contribute to his injury, as alleged in the answer ? Ans.: .

“3. What damages, if any, is the plaintiff Dr. Frank H. Robinson entitled to recover of the defendants Biltmore Dairy Farms, Inc., and Charles Lane for injury to his person? Ans.: .

“4. What damages, if any, is the plaintiff Dr. Frank H. Robinson entitled to recover of the defendants Biltmore Dairy Farms, Inc., and Charles Lane, for injury to his- property ? Ans.: .”

On the verdict the court below rendered judgment for defendants. The plaintiff made certain exceptions and assignments of error and appealed to the Supreme Court.

*W. K. Covington, G. T. Carswell, and Joe W. Ervin for plaintiff.*

*Robinson & J ones for defendants.*

Per CuriaM.

From the argument of counsel and on the entire record, we can find no prejudicial or reversible error. The jury has answered the issue in favor of defendants. The court below, in an able and clear charge (consisting of 36 pages), gave the law applicable to tbe facts. In tbe judgment of tbe court below we find

No error.
# In the United States Court of Federal Claims

OFFICE OF SPECIAL MASTERS

* * * * * * * * * * * * * * * * * * * * *

HELEN KEARNS

, *

* No. 1 8

- 654 V

Petitioner, * Special Master Christian J. Moran

*

v. * Filed: October 6, 2021

*

SECRETARY OF HEALTH * Stipulation; pneumococcal conjugate

AND HUMAN SERVICES, * (Prevnar13) vaccine ; connective

* tissue disease.

Respondent. *

* * * * * * * * * * * * * * * * * * * * *

Ronald C. Homer

, Conway, Homer, P.C.

, Boston

, M A, for Petitioner;

Adriana Teitel , United States Dep’t of Justice, Washington, DC, for Respondent.

UNPUBLISHED DECISION 1

On October 5, 2021 , the parties filed a joint stipulation concerning the

petition for compensation filed by Helen Kearns on May 8 , 201 8 . Petitioner

alleged that the pneumococcal conjugate (Prevnar13) vaccine she received on May

2 8 , 2015, which is contained in the Vaccine I njury Table (the “Table”), 42 C.F.R.

§100.3(a), caused her to suffer from connective tissue disease . Petitioner further

alleges that she suffered the residual effects of this injury for more than six months.

Petitioner represents that there has been no p rior award or settlement of a civil

action for damages on her behalf as a result of her condition.

Respondent denies that the Prevnar13 vaccine caused petitioner to suffer

from c o nnective tissue disease or any other injury.

1 T he E

- Government Act

, 44 U.S.C. § 3501 note (2012) (Federal Management and

Promotion of Electronic Government Services) , requires that the Court post this decision on its

website. Pursuant to Vaccine Rule 18(b), the parties have 14 days to file a motion proposing

redaction of medical information or other information described in 42 U.S.C. § 300aa

- 12(d)(4).

Any redactions ordered by the special master will appear in the document posted on the website.2

Nevertheless, the parties agree to the joint stipulation, attached hereto. The

undersigned finds said stipulation reasonable and adopts it as the decision of the

Court in awarding damages, on the terms set forth therein.

Damages awarded in that stipulation include:

A lump sum payment of $ 92

, 5 00.00 in the form of a check payable to

petitioner. This amount represents compensation for all damages that

would be available under 42 U.S.C. § 300aa

- 15(a).

In the absence of a motion for review filed pursuant to RCFC, Appendix B,

the clerk is directed to enter judgment according to this decision and the attached

stipulation. 2

IT IS SO ORDERED

.

s /Christian J. Moran

Christian J. Moran

Special Master

2 Pursuant to Vaccine Rule 11(a), the parties can expedite entry of judgment by each

party filing a notice renouncing the right to seek review by a United States Court of Fed eral

Claims judge.
Exhibit 99.1

       CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 ADOPTED PURSUANT
                TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In  connection  with the  Quarterly  Report of  NewCom  International,  Inc.,  a
Delaware corporation,  (the "Company") on Form 10-QSB for the period ending June
30,  2003,  as filed with the  Securities  and Exchange  Commission  on the date
hereof  (the  "Report"),  I,  Walter  Grieves,  Chief  Executive  Officer of the
Company,  certify the following  pursuant to Section 18, U.S.C. 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002:

         1.       The Report fully  complies  with the  requirements  of Section
                  13(a) or 15(d) of the Securities Exchange Act of 1934; and

         2.       The information  contained in the report fairly  presents,  in
                  all material respects,  the financial condition and results of
                  operations of the Company.



/s/ Walter Grieves
----------------------------------------
Walter Grieves, Chief Executive Officer
October 23, 2003
Long-Range 

Actuarial 

Balance

Annual 

Balance in 

75th Year

Long-Range 

Actuarial 

Balance

Annual Balance 

in 75th Year

Long-Range 

Actuarial 

Balance

Ann

Balan

75th 

-1.92% -5.70% 0.07% 0.00% -1.86% -5.7

Estimates based on the intermediate assumptions of the 2005 Trustees Report Office of the Chief Actu

Summary Measures and Graphs

Category of Change: Retirement Age

Proposed Provision: Shorten the hiatus in the normal retirement age (speed up the increase to is, increase the NRA by 2 months per year for those attaining age 62 in 2012 through 2017, fivthan in current law, which would increase the NRA 2 months per year for those reaching age 6through 2022.

January 13, 2006

Present Law Change From Present Law in Results with this prov

OASDI Cost Rates and Income Rates

(as a percentage of taxable payroll)

0.005.00

10.0015.0020.0025.00

2005 2015 2025 2035 2045 2055 2065 2075

Year

Percent

Cost rates with this provisionCost rates under present lawIncome rates with this provisionIncome rates under present law

OASDI tax rate schedule 

(employees and employers, each)

1993 and later 6.2%

OASDI Trust Fund Ratio

(assets as a percentage of annual expenditu

0

100200300400500600700800900

1000

2005 2015 2025 2035 2045 205

Year

Percent

Present law with thi